India has the potential to suppress Kovid patches on mass vaccines. Demand and skepticism over the diversion of free jobs under the dual-price regime to a lucrative private market from next month will be largely dependent on the integrity of vaccine manufacturers and state-led immunization authorities. . With no leakages, the doses need to be fairly divided. Given the importance of this mission, there must be transparency among our major vaccine suppliers, the Serum Institute of India (SII) in Pune and Bharat Biotech (BB) in Hyderabad. However, since the epidemic has kept these private companies in the national spotlight, their advertising has been so volatile as to inspire public confidence, be it on price, profitability or productivity.
All that SII chief executive Adar Poonavalla has to say about his company policy is very confusing, to say the least. Scientists at Astrogenica and Oxford will have to pay a royalty SII for any vaccine developed by Pro-Bono. Since it is a public interest project to curb the epidemic, the rights to use that formulation are granted free of charge. SII did not disclose the details of its own license agreement. But, strangely, Poonavalla mentioned in an interview last week CNBC-TV18 It “pays 50% of the price to AstraZeneca as royalty” ₹At Rs 150 per dose, SII supplied a huge amount of central vaccines, the price he quoted on April 6 gave the company space to make a small profit. The company made “sacrifices”, he “super profits”. But in an interview Mint About a fortnight later, the SII chief changed his mind, saying it was “losing money” at that price. Just bad arithmetic? To many, this seemed to justify SII’s job price for private hospitals. ₹600 per dose, obtaining money to expand capacity and thereby cross-subsidizing futures supplies to the Center (50% of production for all domestic producers determined by New Delhi Delhi). Sure, fixed costs in this business are lumpy and outweigh variable input bills. However, SII needs to bring its economy under public scrutiny. It is and will be useful for volumes that can do the same. Its ramp-up promises are often unfulfilled. After a fire broke out in a facility near Pune, Poonavalla assured us that there was no damage to the vaccine product, only to blame the incident for the missing targets.
SII’s rival Bharat Biotech (BB) is the beneficiary of the publicly funded research, which must have helped in the development of the vaccine in partnership with a state organ and therefore we need to give more clarity. But it does not. Last August, its chairperson Krishna Ella pointed to a bottle of water and said, “It costs five times more than our vaccine.” Today, at the price of these jars ₹1,200 per dose for private hospitals. BB provided the same rationale as SII stated. Expansion. However, they need to explain why state governments are overcharging – BB wants ₹Dosage 600 and SII, ₹400 – These pots give immunity to Indians who cannot afford privately given diseases. None of the image of the whip epidemic heroism of greed that people have come out of those prices is good. It’s time for our big vaccine suppliers to come clean, open their books and set the record straight.